Prognostic significance of X-ray cross-complementing group 1 T-77C polymorphism in resected non-small cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 2, 2009, Pages 81-85

  Hsieh, Wei Chung ^a,c   Cheng, Ya Wen ^a   Lin, Cuei Iyuan ^a   Chou, Ming Chih ^a   Chen, Chih Yi ^b   Lee, Huei ^a  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c Da Chien General Hospital   (Taiwan)

Author keywords

NSCLC; Prognosis; XRCC1 genetic polymorphism

Indexed keywords

CISPLATIN; CYTOSINE; GEMCITABINE; PACLITAXEL DERIVATIVE; THYMIDINE; THYMINE; XRCC1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; TAIWAN;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; TAIWAN; TRANSCRIPTION, GENETIC;

EID: 59349097419     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn130     Document Type: Article

References (14)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-903.
3. Seikido YFK, Minna JD. Cancer of the lung. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology 6th ed. Philadelphia: Lippincott-Raven 2001;917-83.
4. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005;23:175-83.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002;346:92-8.
6. de las Penas R, Sanchez-Ronco M, Alberola V, Taron M, Camps C, Garcia-Carbonero R, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006;17:668-75.
7. Yoon SM, Hong YC, Park HJ, Lee JE, Kim SY, Kim JH, et al. The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:885-91.
8. Hu Z, Ma H, Lu D, Zhou J, Chen Y, Xu L, et al. A promoter polymorphism (-77T.C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. Pharmacogenet Genomics 2005;15:457-63.
9. Hao B, Miao X, Li Y, Zhang X, Sun T, Liang G, et al. A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. Oncogene 2006;25:3613-20.
10. Hao B, Wang H, Zhou K, Li Y, Chen X, Zhou G, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res 2004;64:4378-84.
11. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, Saito T, et al. Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC Arg399Gln in Japanese lung cancer risk. Carcinogenesis 2004;25:1395-401.
12. Yin J, Vogel U, Ma Y, Qi R, Sun Z, Wang H. The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population. Lung Cancer 2007;56:153-60.
13. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
14. Sreeja L, Syamala VS, Syamala V, Hariharan S, Raveendran PB, Vijayalekshmia RV, et al. Prognostic importance of DNA repair gene polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln in lung cancer patients from India. J Cancer Res Clin Oncol 2008;134:645-52.